The prevalence of hepatitis B infection in adults in England and Wales

Epidemiology and Infection

Volumn 122, Issue 1, 1999, Pages 133-138

  Gay, N J ^a   Hesketh, L M ^b   Osborne, K P ^a   Farrington, C P ^a   Morgan Capner, P ^b,c   Miller, E ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b ROYAL PRESTON HOSPITAL   (United Kingdom)

^c PHLS Statistics Unit ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B CORE ANTIBODY;

ADOLESCENT; ADULT; AGE; ARTICLE; CHRONIC DISEASE; COST EFFECTIVENESS ANALYSIS; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN CELL; LABORATORY TEST; NORMAL HUMAN; SEROPREVALENCE; UNITED KINGDOM; UROGENITAL TRACT DISEASE; VACCINATION; VIRUS CARRIER;

ADOLESCENT; ADULT; AGE DISTRIBUTION; CARRIER STATE; CROSS-SECTIONAL STUDIES; ENGLAND; FEMALE; HEPATITIS B; HEPATITIS C; HUMANS; MALE; POPULATION SURVEILLANCE; PREVALENCE; RESIDENCE CHARACTERISTICS; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; SEX DISTRIBUTION; TRAVEL; WALES;

EID: 0033041564     PISSN: 09502688     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0950268898001745     Document Type: Article

References (26)

1. van Damme P, Kane M, Meheus A. Integration of hepatitis B vaccination into national immunisation programmes. BMJ 1997; 314: 1033-6.
2. Mortimer PP, Miller E. Commentary: antenatal screening and targeting should be sufficient in some countries. BMJ 1997; 314: 1036-7.
3. Department of Health. Immunisation against infectious disease. London: HMSO, 1996.
4. Gilson RJC, de Ruiter A, Waite J, et al. Hepatitis B virus infection in patients attending a genitourinary medicine clinic: risk factors and vaccine coverage. Sex Trans Inf 1998; 74: 110-5.
5. Unlinked Anonymous Surveys Steering Group. Unlinked anonymous HIV prevalence monitoring programme England and Wales. Data to the end of 1995. London: Department of Health, 1996.
6. Bhatti N, Gilson RJC, Beecham M, et al. Failure to deliver hepatitis B vaccine: confessions from a genito-urinary medicine clinic. BMJ 1991; 303: 97-101.
7. Hart GJ, Dawson J, Fitzpatrick RM, et al. Risk behaviour, anti-HIV and anti-hepatitis B core prevalence in clinic and non-clinic samples of gay men in England. 1991-1992. AIDS 1993; 7: 863-9.
8. Boxall E, Skidmore S, Evans C, Nightingale S. The prevalence of hepatitis B and C in an antenatal population of various ethnic origins. Epidemiol Infect 1994; 113: 523-8.
9. CDSC. Surveillance of viral infection in donated blood: England and Wales, 1996. CDR 1997; 7: 258.
10. Grosheide P, van Damme P. Prevention and control of hepatitis B in the community. Antwerp: Viral Hepatitis Prevention Board Secretariat, 1996.
11. Boxall EH, Flewett TH. Prevalence of HBsAg in UK population. BMJ 1987; 294: 57.
12. Balogun MA, Ramsay ME, Fairley CK, Collins M, Heptonstall J. Acute hepatitis B infection in England and Wales: 1985-96. Epidemiol Infect 1999; 122: 125-131.
13. Hesketh LM, Rowlatt JD, Gay NJ, Morgan-Capner P, Miller E. Childhood infection with hepatitis A and B viruses in England and Wales. CDR 1997; 7: R60-3.
14. Fenn P, Gray A, McGuire A. An economic evaluation of universal vaccination against hepatitis B virus. J Infect 1996; 32: 197-204.
15. Office of Population Censuses and Surveys and General Register Office for Scotland. 1991 Census: ethnic group and country of birth, Great Britain. London: HMSO, 1993.
16. Gay NJ, Ramsay ME, Cohen BJ, et al. The epidemiology of measles in England and Wales since the 1994 vaccination campaign. CDR 1997; 7: R17-21.
17. Gay NJ, Miller E, Hesketh LM, et al. Mumps surveillance in England and Wales supports the introduction of two dose vaccination schedule. CDR 1997; 7: R21-6.
18. Miller E, Tookey PA, Morgan-Capner, P, et al. Rubella surveillance to June 1994: third joint report from the PHLS and the National Congenital Rubella Surveillance Programme. CDR 1994; 4: 146-52.
19. King R, Johnson PJ, White YS, Smith HM, Williams R. Frequency of asymptomatic hepatitis types B and C in an inner city community and relation to possible risk factors. Quart J Med 1991; 80: 641-9.
20. Brook MG, Lever AML, Kelly D, et al. Antenatal screening for hepatitis B is medically and economically effective in the prevention of vertical transmission: three years experience in a London hospital. Quart J Med 1989; 71: 313-7.
21. Ramsay ME, Balogun MA, Collins M, Balraj V. Laboratory surveillance of hepatitis C infection in England and Wales: 1992 to 1996. Commun Dis Public Health 1998; 1: 89-94.
22. Goldberg D, Cameron S, McMenamin J. Hepatitis C virus antibody prevalence among injecting drug users in Glasgow has fallen but remains high. Commun Dis Public Health 1998; 1: 95-7.
23. Majid A, Holmes R, Desselburger U, Simmonds P, McKee A. Molecular epidemiology of hepatitis C infection amongst intravenous drug users in rural communities. J Med Viron 1995; 46: 48-51.
24. El-Dalil AA, Jayaweera DT, Walzman M, et al. Hepatitis B markers in heterosexual patients attending two genitourinary medicine clinics in the West Midlands. Genitourin Med 1997; 73: 127-30.
25. Mangtani P, Hall AJ, Normand CEM. Hepatitis B vaccination: the cost effectiveness of alternative strategies in England and Wales. J Epidemiol Comm Hlth 1995; 49: 238-44.
26. Williams JR, Nokes DJ, Anderson RM. Targeted hepatitis B vaccination - a cost effective strategy for the UK? J Epidemiol Comm Hlth 1996; 50: 667-73.